All News

Tom Brady Dyes Hair Orange to Raise Funds for Pediatric Cancer, Cancer Choir With a Profane Name Performs for Pope Francis and More

June 10th 2022

From Tampa Bay Buccaneers quarterback Tom Brady letting children with cancer dye his hair orange to the name of a cancer drug causing controversy at the Scripps National Spelling Bee, here’s what’s happening in the cancer space this week.

Educated Patient® Prostate Cancer Summit Treatment in Localized Disease Panel: May 21, 2022

June 10th 2022

Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

Zenocutuzumab ‘Offers Potential New Standard of Care’ for NRG1-Positive Solid Cancers

June 9th 2022

With no approved therapies for NRG-1 cancers, zenocutuzumab offers a promising treatment option for this patient population.

Pre- and Post-Surgical Jakafi Plus Chemo Shows Potential in Advanced Ovarian Cancer

June 9th 2022

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

How Does a Cancer Survivor Obtain Life Insurance?

June 9th 2022

One of the most loving things I can do for my family is to purchase life insurance, but my application was turned down, presumably because of my cancer history.

Keytruda Demonstrates Significant Improvement for Some Patients with Melanoma

June 9th 2022

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.

Educated Patient® Prostate Cancer Summit Approaches to Radiation Presentation: May 21, 2022

June 9th 2022

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

Durable Responses Continue with Keytruda Plus Chemoradiation in Previously Untreated Non-Small Cell Lung Cancer

June 8th 2022

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

Jemperli Eliminated All Signs of Rectal Cancer in Small Clinical Trial, Warranting Further Research

June 8th 2022

One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.

My Third and Fourth Cancer Opinions Gave Me a Second Chance at Life

June 8th 2022

Getting other medical opinions for my cancer diagnosis not only saved my life but also taught me self-care.

Exkivity Delivers Minimal Benefit to Patients with Non-Small Cell Lung Cancer and Brain Metastases

June 8th 2022

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

Educated Patient® Prostate Cancer Summit Overview of Surgery Presentation: May 21, 2022

June 8th 2022

Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

Ifosfamide Induces ‘Subtle’ Survival Improvement Over Hycamtin-Cyclophosphamide Combo in Ewing Sarcoma

June 7th 2022

The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.

A Couple’s Cancer Journey Reversed in the Blink of an Eye

June 7th 2022

Actress and comedian Jessica St. Clair and her husband, Dan O’Brien, share their roles of partner and parent, but also patient and cancer caregiver, as their roles were reversed in the blink of an eye.

Is It Possible to See into Your Cancer Future?

June 7th 2022

I was approached with the opportunity to ghostwrite for an author who was writing about his cancer journey. I’m still baffled by the timing, but that experience shifted into my eventual cancer journey.

Enhertu Fulfills ‘Big Unmet Need’ for Patients with HER2-Low Metastatic Breast Cancer

June 7th 2022

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

Adding Darzalex to Popular Multiple Myeloma Treatment Regimen May Lead to Durable Responses

June 7th 2022

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer

June 6th 2022

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer

June 6th 2022

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Patient Advocates Represent a Much-Needed Lifeline for People Who are Dealing with Cancer

June 6th 2022

Having someone beside you to accompany you during doctor's visits to take notes or having someone to help you find the right specialist or even to just help research what treatment options are available can be incredibly helpful.

Early Study Findings Show Novel Drug Elicits Promising Results in Metastatic Breast Cancers

June 6th 2022

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

SOT101 With or Without Keytruda Shows Promise, Safety in Treating Advanced Solid Tumors

June 6th 2022

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

June 5th 2022

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Trodelvy Reduces Risk of Disease Progression in Certain Patients With Metastatic Breast Cancer

June 5th 2022

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Lenvima Plus Keytruda May Become Next Standard-of-Care Treatment Option for Advanced Kidney Cancer

June 5th 2022

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Adcetris Plus Chemo ‘Potentially Cured’ Some Patients With Hodgkin Lymphoma

June 5th 2022

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

Tibsovo Plus Vidaza Is Beneficial for Patients With IDH1-Mutant Acute Myeloid Leukemia

June 4th 2022

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

Cabometyx Failed to Improve Survival in Advanced Bladder Cancer

June 4th 2022

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

New Drug May Mitigate Incidence, Severity of Chemotherapy-Related Oral Mucositis in Patients With Head and Neck Cancer

June 4th 2022

Avasopasem manganese is the first drug that has been shown to reduce the incidence and severity of chemotherapy-related oral mucositis in patients with head and neck cancer, research showed.

Treatment With Vonjo May Elicit Fewer Side Effects Than Other Available Therapies in Myelofibrosis, a Rare Type of Blood Cancer

June 4th 2022

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.